Kangstem Soothes Investors, Finds Hope In New Trials For Furestem In Atopic Dermatitis

 
• By Jung Won Shin

After the much anticipated Phase III South Korean clinical trial of its cord blood-derived stem cell therapy for atopic dermatitis failed to meet its primary endpoint, Kangstem Biotech shifts tactics to focus on repeated dose and combo trials in the hope of better efficacy data.

Stem cell
Furestem-AD Fails To Meet Primary Endpoint, But Hopes Not Lost • Source: Shutterstock

More from South Korea

More from Focus On Asia